HPV Vaccines and Immunotherapies Conference

描述（由申请人提供）：宫颈癌仍然是一个严重的问题，在世界范围内，这种癌症的最大负担发生在第三世界的贫困妇女谁有限或没有获得医疗服务。 高危型人乳头瘤病毒（HPV）感染是产生宫颈癌所必需的，因此开发有效的预防和/或治疗HPV感染的疫苗可以大大降低疾病的发病率，特别是在不发达国家，并且是所有抗宫颈癌策略中最有效的。 一种针对最常见的癌症相关HPV（HPV 16）的HPV疫苗在涉及1533名年轻性活跃女性的原则性试验证明中显示出100%的有效性。 这一重要发现为开发更广泛特异性的疫苗开辟了道路，这些疫苗可用于大规模免疫接种，以预防宫颈癌和其他HPV相关的恶性疾病。 鉴于疫苗试验的这些非常令人鼓舞的结果，现在是时候将HPV免疫学的所有专家聚集在一个会议上，这将使我们不仅能够“说明”这些疫苗的现状，而且还能说明宿主对HPV介导的疾病的防御，并开始展望全面开发抗HPV疫苗和免疫疗法的最佳方法，如何有效地提供这些疫苗和免疫疗法，至关重要的是，如何以最适当的形式在全世界提供这些信息。 正在计划召开一次会议，深入探讨所有这些问题：HPV疫苗和免疫疗法会议，将于2003年7月10日至13日在英国剑桥举行。 本次会议将汇集HPV免疫学和免疫治疗领域的主要参与者，并将作为培训对HPV免疫学和宫颈癌预防/治疗领域感兴趣的年轻研究人员的论坛。 该提案要求提供资金，以支持年轻研究人员（学生和博士后研究员）前往HPV疫苗和免疫治疗会议，本次会议将为他们提供在这一重要领域进行培训的独特机会。 还要求为会议的一般组织费用提供资金。

DESCRIPTION (provided by applicant): Cervical cancer remains a serious problem worldwide, with the greatest burden on this cancer occurring in poor women in the Third World who have limited or no access to medical services. High risk human papillomavirus (HPV) infection is necessary to produce cervical cancer, and thus the development of effective vaccines for the prevention and/or treatment of HPV infections could drastically reduce the incidence of disease, particularly in underdeveloped countries and be the most effective anti-cervical cancer strategy of all. An HPV vaccine targeted against the most common cancer associated HPV (HPV16) has shown 100 percent efficacy in a proof of principle trial involving 1533 young sexually active women. This crucial finding opens the way for the development of vaccines of broader specificity that can then be used for mass immunization to prevent cervical cancer and hopefully other HPV associated malignant disease. It is timely, in view of these immensely encouraging results from vaccine trials, to bring together all experts in HPV immunology in a conference that will allow us to "make the point" not only on the status of these vaccines, but also on host defense to HPV-mediated disease, and begin to look ahead at the best ways to fully develop anti-HPV vaccines and immunotherapies, how to deliver these effectively and, crucially, how to make them available worldwide in the most appropriate form. A Conference is being planned to address in depth all of these issues: The HPV Vaccines and Immunotherapies Conference, which will be held in Cambridge, UK, July 10-13, 2003. This conference will bring together the major players in the fields of HPV immunology and immunotherapy, and will serve as a forum for the training of young investigators interested in the areas of HPV immunology and cervical cancer prevention/therapy. This proposal requests funds to support travel to the HPV Vaccines and Immunotherapies Conference by young investigators (students and postdoctoral fellows) for whom this conference will provide a unique opportunity for training in this important field. Funds for general organizational expenses for the Conference are also requested.